Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.63 |
| ▸ | GAA | P10253 | 9/20 | 0.63 |
| ▸ | MAPT | P10636 | 8/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | HTT | P42858 | 5/20 | 0.63 |
| ▸ | HPGD | P15428 | 6/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.56 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.56 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 5/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | ALPG | P10696 | 1/20 | 0.54 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1132877 | 1.00 | MEN1 (0.63) | MEN1KMT2AGAAMAPTKDM4E | |
| SCHEMBL1132128 | 0.84 | MAPT (0.63) | MEN1KMT2AGAAMAPTKDM4E | |
| SCHEMBL1132158 | 0.84 | MAPT (0.63) | MEN1KMT2AGAAMAPTKDM4E | |
| SCHEMBL1132176 | 0.84 | MEN1 (0.71) | MEN1KMT2AGAAMAPTKDM4E | |
| SCHEMBL1132355 | 0.84 | MAPT (0.47) | MEN1KMT2AGAAMAPTKDM4E | |
| SCHEMBL1132125 | 0.84 | MEN1 (0.71) | MEN1KMT2AGAAMAPTKDM4E | |
| SCHEMBL30602635 | 0.84 | MEN1 (0.71) | MEN1KMT2AGAAMAPTKDM4E | |
| SCHEMBL1132357 | 0.84 | MAPT (0.47) | MEN1KMT2AGAAMAPTKDM4E | |
| SCHEMBL1132318 | 0.81 | MEN1 (0.67) | MEN1KMT2AGAAMAPTKDM4E | |
| SCHEMBL1132320 | 0.81 | MEN1 (0.67) | MEN1KMT2AGAAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512066-B2 | Enhancers of protein degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2016-12-06 | — | — | US | claimed |
| US-20120282629-A1 | Enhancers of Protein Degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2012-11-08 | — | — | US | claimed |
| EP-2488485-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-08-22 | — | — | EP | claimed |
| WO-2011020883-A9 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-07-12 | — | — | WO | claimed |
| WO-2011020883-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2011-02-24 | — | — | WO | claimed |
| EP-2287149-A1 | Enhancers of protein degradation | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2011-02-23 | — | — | EP | claimed |
| US-9512066-B2 | Enhancers of protein degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20120282629-A1 | Enhancers of Protein Degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2012-11-08 | — | — | US | disclosed |
| EP-2488485-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011020883-A9 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-07-12 | — | — | WO | disclosed |
| WO-2011020883-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2011-02-24 | — | — | WO | disclosed |
| EP-2287149-A1 | Enhancers of protein degradation | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2011-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282629-A1 | Enhancers of Protein Degradation | HTT, HYPK, TFEB | MEN1 3413/4885KMT2A 2000/4885GAA 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.